Monoethylglycinexylidine

CAS : 7728-40-7

Ref. 3D-HAA72840

Informations sur le produit

• Nom: Monoethylglycinexylidine
• Synonymes: 2-(Ethylamino)-2′,6′-acetoxylidide, 2′,6′-Acetoxylidide, 2-(ethylamino)-, Monoethylglycinexylidide, Monoethylglycylxylidide, N-(2,6-Dimethylphenyl)-2-(ethylamino)acetamide, N-(N-Ethylglycyl)-2,6-xylidine, N-Ethylglycinexylidide, N1-(2,6-dimethylphenyl)-2-(ethylamino)acetamide, Norlidocaine, acetamide, N-(2,6-dimethylphenyl)-2-(ethylamino)-, ω-Ethylamino-2′,6′-dimethylacetanilide

Description

Monoethylglycinexylidine (MEGX) is a drug that has been shown to be effective in the treatment of chronic viral hepatitis. It has an activity index of 0.6-2.0 and can be used as a diagnostic tool for hepatic impairment. MEGX has also been found to be more effective in patients with primary sclerosing cholangitis than in those with non-primary sclerosing cholangitis. MEGX inhibits the P450 enzyme, which is involved in the metabolism of xenobiotics and endogenous compounds, and also inhibits Lidocaine-induced bronchoconstriction. The structural analysis of MEGX showed that it forms a stable complex with the active site of P450 enzymes, but does not form stable complexes with other enzymes such as cytochrome P450 reductase or epoxide hydrolase. In vivo experiments have shown that MEGX inhibits liver regeneration in mice by inhibiting hepatocyte

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 206.28 g/mol
• Formule: C₁₂H₁₈N₂O
• Degré de pureté: Min. 95%